11/20
08:57 am
rnxt
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial [Yahoo! Finance]
Low
Report
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial [Yahoo! Finance]
11/20
08:45 am
rnxt
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Medium
Report
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
11/14
08:12 am
rnxt
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights [Yahoo! Finance]
Low
Report
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights [Yahoo! Finance]
11/14
08:00 am
rnxt
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
Low
Report
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
9/26
07:46 am
rnxt
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully [Yahoo! Finance]
Medium
Report
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully [Yahoo! Finance]
9/25
08:30 am
rnxt
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
Low
Report
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
9/19
08:30 am
rnxt
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
Medium
Report
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
9/12
08:11 am
rnxt
RenovoRx, Inc. (NASDAQ: RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $8.25. They now have a "buy" rating on the stock.
Medium
Report
RenovoRx, Inc. (NASDAQ: RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $8.25. They now have a "buy" rating on the stock.
8/27
10:53 am
rnxt
MyTomorrows partners with pancreatic cancer pressure group to drive trials [Yahoo! Finance]
Low
Report
MyTomorrows partners with pancreatic cancer pressure group to drive trials [Yahoo! Finance]
8/27
08:45 am
rnxt
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York [Yahoo! Finance]
Low
Report
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York [Yahoo! Finance]
8/27
08:30 am
rnxt
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York
Low
Report
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York